Have a feature idea you'd love to see implemented?
Let us know!
IMRX Immuneering Corp
Price (delayed)
$2.11
Market cap
$65.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.97
Enterprise value
$24.55M
Highlights
The debt has declined by 7% year-on-year
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of IMRX
Market
Valuations
Earnings
Shares outstanding
31.05M
Market cap
$65.52M
Enterprise value
$24.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$58.07M
EBITDA
-$57.34M
Free cash flow
-$52.51M
Per share
Balance sheet
Liquidity
EPS
-$1.97
Free cash flow per share
-$1.76
Book value per share
$1.95
Revenue per share
$0
TBVPS
$2.06
Total assets
$68.56M
Total liabilities
$10.84M
Debt
$4.24M
Equity
$57.72M
Working capital
$48.34M
Debt to equity
0.07
Current ratio
7.99
Quick ratio
7.32
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-69.1%
Return on equity
-79.2%
Return on invested capital
-341.5%
Return on capital employed
-94.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMRX stock price
How has the Immuneering stock price performed over time
Intraday
3.43%
1 week
8.76%
1 month
-2.31%
1 year
-69.86%
YTD
-71.29%
QTD
-15.26%
Financial performance
How have Immuneering's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.82M
Net income
-$58.07M
Gross margin
N/A
Net margin
N/A
The gross profit has shrunk by 100% YoY
Immuneering's revenue has shrunk by 100% YoY
The net income has declined by 12% year-on-year and by 3.6% since the previous quarter
The operating income has declined by 10% year-on-year and by 2.2% since the previous quarter
Growth
What is Immuneering's growth rate over time
Valuation
What is Immuneering stock price valuation
P/E
N/A
P/B
1.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 5% year-on-year and by 3.1% since the previous quarter
Immuneering's equity has decreased by 45% YoY and by 13% from the previous quarter
IMRX's P/B is 17% less than its last 4 quarters average of 1.3
Immuneering's revenue has shrunk by 100% YoY
Efficiency
How efficient is Immuneering business performance
IMRX's return on invested capital has dropped by 86% year-on-year and by 40% since the previous quarter
The ROE has plunged by 64% YoY and by 20% from the previous quarter
The ROA has dropped by 57% year-on-year and by 18% since the previous quarter
Dividends
What is IMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMRX.
Financial health
How did Immuneering financials performed over time
The quick ratio has plunged by 58% YoY and by 17% from the previous quarter
The current ratio has dropped by 55% year-on-year and by 15% since the previous quarter
The debt is 93% smaller than the equity
IMRX's debt to equity has surged by 75% year-on-year
Immuneering's equity has decreased by 45% YoY and by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.